Multiple effects of amprenavir against Candida albicans

FEMS Yeast Research

Volumn 10, Issue 2, 2010, Pages 221-224

  Braga Silva, Lys A ^a,b   Mogami, Sheijy S V ^a   Valle, Roberta S ^a   Silva Neto, Ignácio D ^a   Santos, André L S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto de Química   (Brazil)

Author keywords

Amprenavir; Aspartic peptidase inhibitor; Candida albicans; Fungal biology

Indexed keywords

AMPRENAVIR; ESTERASE; GLYCOCONJUGATE; INDINAVIR; LOPINAVIR; MANNOSE; NELFINAVIR; RITONAVIR; SAQUINAVIR; SIALIC ACID; STEROL;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CHEMOTHERAPY; DRUG EFFECT; ENZYME ACTIVITY; FUNGUS GROWTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; ULTRASTRUCTURE;

ASPARTIC ACID ENDOPEPTIDASES; BIOFILMS; BLOOD; CANDIDA ALBICANS; CANDIDIASIS; CARBAMATES; CULTURE MEDIA; FUNGAL PROTEINS; FUNGEMIA; HIV PROTEASE INHIBITORS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SULFONAMIDES;

CANDIDA ALBICANS;

EID: 76349109672     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2009.00595.x     Document Type: Article

References (20)

1. Borg-von Zepelin M, Meyer I, Thomssen R, Wurzner R, Sanglard D, Telenti A Monod M (1999) HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 113 : 747 751.
2. Braga-Silva LA, Mesquita DG, Ribeiro MD, Carvalho SM, Fracalanzza SE Santos ALS (2009) Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases. Braz J Med Biol Res 42 : 765 770.
3. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M Cauda R (1999) In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180 : 448 453.
4. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T Ghannoum MA (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183 : 5385 5394.
5. De Araújo Soares RM, Soares RMA, Alviano DS, Angluster J, Alviano CS Travassos LR (2000) Identification of sialic acids on the cell surface of Candida albicans. Biochim Biophys Acta 1474 : 262 268.
6. Eggimann P, Garbino J Pittet D (2003a) Management of Candida species infections in critically ill patients. Lancet Infect Dis 3 : 772 785.
7. Eggimann P, Garbino J Pittet D (2003b) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3 : 685 702. (Pubitemid 37345347)
8. Fung HB, Kirschenbaum HL Hameed R (2000) Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther 22 : 549 572.
9. Kanafani ZA Perfect JR (2008) Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 46 : 120 128.
10. Korting HC, Schaller M, Eder G, Hamm G, Böhmer U Hube B (1999) Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Ch 43 : 2038 2042.
11. Naglik JR, Challacombe SJ Hube B (2003) Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol R 67 : 400 428.
12. Pietrella D, Bistoni G, Corbucci C, Perito S Vecchiarelli A (2006) Candida albicans mannoprotein influences the biological function of dendritic cells. Cell Microbiol 8 : 602 612.
13. Portela MB, Souza IPR, Costa EMMB, Hagler AN, Soares RMA Santos ALS (2004) Differential recovery of Candida species from subgingival sites in HIV-positive and healthy children from Rio de Janeiro, Brazil. J Clin Microbiol 42 : 5925 5927.
14. Sangetha S, Zuraini Z, Suryani S Sasidharan S (2009) In situ TEM and SEM studies on the antimicrobial activity and prevention of Candida albicans biofilm by Cassia spectabilis extract. Micron 40 : 439 443.
15. Santos ALS, Carvalho IM, Silva BA, Portela MB, Alviano CS Soares RMA (2006) Secretion of serine peptidase by a clinical strain of Candida albicans: influence of growth conditions and cleavage of human serum proteins and extracellular matrix components. FEMS Immunol Med Mic 46 : 209 220.
16. Slifkin M (2000) Tween 80 opacity test responses of various Candida species. J Clin Microbiol 38 : 4626 4628.
17. Smolenski G, Sullivan PA, Cutfield SM Cutfield JF (1997) Analysis of secreted aspartic proteinases from Candida albicans: purification and characterization of individual Sap1, Sap2 and Sap3 isoenzymes. Microbiology 143 : 349 356.
18. Soares RMA, Angluster J, De Souza W Alviano CS (1995) Carbohydrate and lipid components of hyphae and conidia of human pathogen Fonsecaea pedrosoi. Mycopathologia 132 : 71 77.
19. Stewart K Abad-Zapatero C (2001) Candida proteases and their inhibition: prospects for antifungal therapy. Curr Med Chem 8 : 941 948.
20. White TC Agabian N (1995) Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 177 : 5215 5221.